18

19

20

21

22

23

24

25

26

27

28

1 2 3 4 5 UNITED STATES DISTRICT COURT 6 NORTHERN DISTRICT OF CALIFORNIA 7 8 SANDRA L. KINNEY, et al., No. C-12-4477 EMC 9 Plaintiffs, RELATED TO 10 No. C-12-4478 EMC v. No. C-12-4615 EMC 11 BRISTOL-MYERS SQUIBB COMPANY, et No. C-12-4616 EMC No. C-12-4617 EMC 12 No. C-12-4619 EMC Defendants. No. C-12-4633 EMC 13 No. C-12-4641 EMC No. C-12-4642 EMC 14 No. C-12-4803 EMC AND ALL RELATED ACTIONS. 15 ORDER STAYING LITIGATION 16 PENDING DECISION BY MDL JUDICIAL PANEL 17

At a hearing held on November 30, 2012, the Court discussed with the parties whether there should be a stay in the above-referenced lawsuits in light of Bristol-Myers and Sanofi's motion to transfer and consolidate with the Judicial Panel on Multidistrict Litigation (which was filed on October 15, 2012). See Docket No. 19 (notice). Having considered the parties' positions, as articulated in their joint case management statement and at the hearing, the Court concludes that a stay is warranted. There is a reasonable likelihood that issues currently before this Court (e.g., fraudulent joinder, CAFA jurisdiction, and/or procedural misjoinder) will arise in other Plavix cases filed in other district courts. Moreover, Plaintiffs have not adequately established that they would be prejudiced by any delay resulting from a stay, particularly where the stay is likely to be brief in

length. See Docket No. 24 (CMC St. at 4) (stating Defendants' best estimate that the panel hearing
will take place on January 31, 2013).
Accordingly, the Court hereby STAVS the litigation in each of the above-referenced action

Accordingly, the Court hereby **STAYS** the litigation in each of the above-referenced actions pending a decision by the MDL Judicial Panel on the motion to transfer and consolidate.

IT IS SO ORDERED.

Dated: December 3, 2012

United States District Judge